Mount Sinai’s Elvin Wagenblast Honored by Leukemia & Lymphoma Society for Advancing Research in Childhood Leukemia
The Leukemia & Lymphoma Society (LLS) has honored Elvin Wagenblast, PhD, Assistant Professor of Oncological Sciences, and Pediatrics, at the Icahn School of Medicine at Mount Sinai with the 2024 LLS-CDP Special Fellow Achievement Award. Dr. Wagenblast was recognized for his groundbreaking work using cutting-edge genetic tools to uncover the origins and mechanisms of childhood leukemia.
Dr. Wagenblast received the award on Sunday, December 8, during the LLS Research Awards & Networking Event in San Diego, held in conjunction with the 66th American Society of Hematology (ASH) Annual Meeting & Exposition.
"Dr. Wagenblast's research exemplifies the innovative spirit driving progress in the fight against blood cancers," said Gwen Nichols, MD, Chief Medical Officer of LLS. "His work investigating how leukemia develops in children is shedding new light on disease mechanisms and paving the way for targeted treatments that could significantly improve outcomes for young patients."
Originally from Germany, Dr. Wagenblast obtained his PhD at Cold Spring Harbor Laboratory, focusing on breast cancer, before transitioning to leukemia research during his postdoctoral fellowship at the Princess Margaret Cancer Center in Toronto. He joined Mount Sinai in 2022, where he leads an eight-member lab dedicated to unraveling the complexities of childhood leukemia.
Dr. Wagenblast’s research focuses on the paradox of childhood leukemia: while cancer is often associated with aging, leukemia is the most common cancer in children. His lab is investigating how unique molecular processes during early development predispose children to blood cancers. Using CRISPR/Cas9 technology, he is modeling specific genetic mutations to uncover why certain normal blood stem cells transform into malignant leukemia cells.
One key project has focused on a subtype of acute myeloid leukemia (AML) characterized by a devastating genetic mutation with an overall survival rate below 10 percent at four years. By modeling this mutation in blood stem cells, Dr. Wagenblast’s team has identified potential drug targets, a critical step toward developing treatments tailored to childhood leukemia rather than adapting therapies designed for adults.
“Our work aims to bridge the gap in understanding between adult and pediatric blood cancers,” said Dr. Wagenblast. “Children’s leukemias are biologically distinct and require dedicated research to find effective, targeted treatments. This recognition from LLS underscores the importance of our mission.”
Dr. Wagenblast credits the collaborative environment at Mount Sinai as a driving force behind his success. His lab works closely with the the Institute for Regenerative Medicine, The Mindich Child Health and Development Institute, and the Center for Advancement of Blood Cancer Therapies, among others at The Tisch Cancer Institute at the Icahn School of Medicine.
“This award reflects the collective efforts of many departments and institutions at Mount Sinai,” he said. “I’m deeply grateful for the support of my colleagues and leaders, like Ramon Parsons, MD, PhD, Sarah Millar, PhD, and Erini Papapetrou, MD, PhD. Finally, I would like to thank the Leukemia & Lymphoma Society for its continued investment in our work, which has been instrumental in shaping my research path and advancing our understanding of childhood leukemia.”
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.